Chagas Disease Clinical Trial
Official title:
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment, Retrospective Cohort
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission. Pharmacological treatment is given to prevent development of cardiac and gastrointestinal sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They both has proven efficacy for acute face treatment, with different security profiles. There are not enough adequate studies comparing both drugs made in a large number of subjects. Investigators will study 900 patients treated with both drugs and compare security and efficacy in a retrospective cohort.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01162967 -
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
|
Phase 2 | |
| Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
| Active, not recruiting |
NCT04024163 -
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
|
Phase 3 | |
| Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
| Completed |
NCT03892213 -
Pharmacokinetic Drug-Drug Interaction Study
|
Phase 1 | |
| Recruiting |
NCT00875173 -
Selenium Treatment and Chagasic Cardiopathy (STCC)
|
Phase 3 | |
| Recruiting |
NCT03704181 -
Colchicine for Patients With Chagas´ Disease( B1 Stage)
|
Phase 2 | |
| Active, not recruiting |
NCT03378661 -
BENDITA BEnznidazole New Doses Improved Treatment and Associations
|
Phase 2 | |
| Completed |
NCT01927224 -
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
|
Phase 1 | |
| Completed |
NCT01006486 -
Outcomes of an Anticoagulation Clinic in an University Hospital
|
Phase 4 | |
| Completed |
NCT00123916 -
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
|
Phase 3 | |
| Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
| Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
| Completed |
NCT01874795 -
Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
|
N/A | |
| Completed |
NCT01006473 -
Exercise Training in Chagas Cardiomyopathy
|
Phase 4 | |
| Completed |
NCT02386358 -
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
|
Phase 3 | |
| Not yet recruiting |
NCT05477953 -
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
|
||
| Completed |
NCT02346123 -
Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
|
N/A | |
| Recruiting |
NCT02295215 -
Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
|
N/A |